Jefferies analyst, David Steinberg, reiterated his Buy rating on shares of Nektar Therapeutics (NASDAQ: NKTR) after the company announced positive ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE